Pharmaceutical companies are offering new drugs referred to as immune modulators for the treatment of skin diseases such as eczema. These drugs are used to externally treat the skin without changing the immune system of the body. In addition, unlike topical steroids, these new medications do not cause thinning of the skin and breaking of superficial blood vessels. Tacrolimus (Protopic) and Pimecrolimus (Elidel) are major drugs available for the treatment of eczema.
North America was the largest region in the dermatology drugs market in 2017, accounting for around 31% market share. This can be attributed to a large number of affluent patients and generous reimbursement within the US pharma market. Asia Pacific was the second largest region accounting for around 29% market share. Africa was the seventh largest region accounting for around 3% market share.
- Time Series: Five years historic and forecast.
- Data: Market value in $ billions.
- Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.
- Johnson & Johnson
- Allergan Plc.
- Galderma S.A.
- Novartis AG
- GlaxosmithKline Plc.
- Bayer AG
- LEO Pharma A/S
For more information about this report visit https://www.researchandmarkets.com/research/qq4gf6/dermatology_drugs?w=4